TP53I13: A Tumor Protein as a Potential Drug Target and Biomarker

Target Name: TP53I13

NCBI ID: G90313

TP53I13

TP53I13: A Tumor Protein as a Potential Drug Target and Biomarker

Tumor suppressor proteins are essential for maintaining tissue homeostasis and preventing cancer growth. p53 is one of the most well-known tumor suppressor proteins that are often mutated in cancer. The p53 gene has four splice variants, including TP53I13, which is a splicing variant that is predominantly expressed in human tissues. In this article, we will discuss TP53I13 as a potential drug target and biomarker in cancer.

Structure and Function

TP53I13 is a 13-kDa protein that is composed of 115 amino acid residues. It has a molecular weight of 13 kDa and a calculated pI of 6.9. The protein has a single transmembrane domain and a N-terminus that is involved in protein-protein interactions. TP53I13 is a potent tumor suppressor protein that can induce cell cycle arrest and apoptosis in various cancer cell types.

In Oncogenic Processes

TP53I13 has been implicated in several oncogenic processes, including DNA damage repair, apoptosis, and cell cycle regulation. It has been shown to regulate DNA double-strand break repair by preventing homologous recombination and by enhancing the activity of the DNA repair enzyme, NIP/TAQ. TP53I13 has also been shown to induce apoptosis in various cancer cell types through the production of pro-apoptotic proteins, including Bax and p53.

As a Potential Drug Target

The p53 gene has been a focus of drug development for various cancer types due to its potential as a drug target. inhibitors of TP53 have been shown to be effective in treating various types of cancer, including breast, ovarian, and colorectal cancers. These inhibitors work by binding to specific regions of the p53 protein, leading to its inhibition and preventing it from functioning as a tumor suppressor.

In addition to its potential as a drug target, TP53I13 has also been identified as a potential biomarker for cancer. The loss of p53 has been observed in various types of cancer, including breast, ovarian, and colorectal cancers. The expression of TP53I13 has also been shown to be associated with cancer-related survival, with higher expression levels being associated with poor prognosis.

Conclusion

TP53I13 is a tumor suppressor protein that has been shown to play a crucial role in the regulation of apoptosis and the detoxification of DNA damage. Its potential as a drug target and biomarker makes it an attractive target for cancer therapies. Further research is needed to fully understand the mechanisms of TP53I13 as a drug target and its potential as a biomarker for cancer.

Protein Name: Tumor Protein P53 Inducible Protein 13

Functions: May act as a tumor suppressor. Inhibits tumor cell growth, when overexpressed

The "TP53I13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TP53I13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets